Under the terms of the Withdrawal Agreement and the Windsor Framework, PPP authorisations in NI must comply with the relevant EU MRLs (maximum residue levels).
The EU MRL review programme can result in EU MRLs being lowered and PPPs authorised in NI may be affected.
Find out the status of ongoing and upcoming EU MRL reviews
The present ebulletin covers the EU (Standing Committee on Plants, Animals, Food and Feed) SCoPAFF meetings in February and April 2024.
February meeting: Future EU MRL amendments: publication expected mid 2024
In February 2024 the EU SCoPAFF agreed to changes to EU MRLs for a number of active substances under Regulation (EC) No 396/2005.
It is expected that EU MRLs will be amended for the following active substances:
- deltamethrin
- metalaxyl/metalaxyl-M
- thiabendazole
- trifloxystrobin
- diathianon
The Implementing Regulations have been published for the above active substances.
For dithianon, the MRLs are expected to come into force on the 5 December 2024.
For deltamethrin, metalaxyl/metalaxyl-M, thiabendazole and trifloxystrobin the MRLs are expected to come into force on the 11 December 2024.
April meeting: Future EU MRL amendments: publication expected mid-late 2024
In April 2024, the EU SCoPAFF agreed to changes to EU MRLs for a number of active substances under Regulation (EC) No 396/2005.
If these pass scrutiny by the European Parliament and Council we can expect the publication of EU Implementing Regulations for the revised MRLs in the next 4-6 months. The MRLs are likely to come into force 6 months following publication i.e. by early-mid 2025.
It is expected that EU MRLs will be amended for the following active substances:
- benomyl
- carbendazim
- thiophanate-methyl
- cyproconazole
- spirodiclofen
- napropamide
- pyridaben
- tebufenpyrad
Find out which commodities are affected by searching for the active substance in the EU MRL database.
Related changes proposed to EU MRLs for deltamethrin, metalaxyl/metalaxyl-M, thibendazole, trifloxystrobin, dithianon, cyproconazole, spirodiclofen, napropamide, pyridaben and tebufenpyrad currently appear in the “not yet applicable” column. Related changes proposed to EU MRLs for benomyl, carbendazim and thiophanate-methyl will shortly appear in the “not yet applicable” column.
The list above does not include EU MRLs resulting from applications to raise EU MRLs, e.g. to support new PPP uses, or proposals to list active substances on Annex IV of Regulation (EC) No 396/2005 (actives not subject to MRLs).
What HSE will do
HSE will aim to identify NI PPP authorisations that require amending or withdrawing as a result of new EU MRLs coming into force and contact authorisation holders that are affected.
What NI PPP authorisation holders are advised to do
Authorisation holders are advised to check that their NI PPP authorisations comply with the amended EU MRLs. Authorisation holders who identify any NI PPP authorisations that will not comply with the amended EU MRLs are advised to contact us.
Authorisation holders should review the European Food Safety Authority’s reasoned opinions which identify data/information that is unavailable but is required to retain MRLs following EU MRL reviews.
These appear as footnotes in the EU MRL database and authorisation holders wishing to retain EU MRLs should submit the data/information by the deadline in an application to an EU Member State.
Find guidance on submitting data to confirm EU MRLs
Contact us
If you have any questions relating to this ebulletin, please contact us.
|
